Anatomical terms of motion

Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer

Retrieved on: 
Thursday, February 15, 2024
Quality of life, Regeneron Pharmaceuticals, Anatomical terms of motion, Patient, AbbVie, Therapy, Procter & Gamble, Eye, Flexion Therapeutics, Management

BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Steve Meyers as Chief Commercial Officer.

Key Points: 
  • BEDFORD, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Steve Meyers as Chief Commercial Officer.
  • “As we continue our commitment to advancing our drug portfolio in order to enhance the quality of life for patients, I am thrilled to announce the promotion of Steve Meyers to the role of Chief Commercial Officer,” said Antony Mattessich, CEO of Ocular Therapeutix.
  • With his expertise and dedication, I am confident he will play a pivotal role in driving Ocular’s commercial efforts forward.”
    “I am truly honored by this opportunity to serve as Chief Commercial Officer," said Steve Meyers.
  • Prior to joining Ocular, Mr. Meyers served as Vice President of Sales at Flexion Therapeutics in the orthopedic space.

OnePlus Unveils its First Foldable Smartphone in the U.S. and Canada - the OnePlus Open

Retrieved on: 
Thursday, October 19, 2023
Emerald, Well, OnePlus, ROM, Anatomical terms of motion, Microsoft, Architecture, Sony, Durability, IEEE 802.11be, Glass, Partnership, Lens, XCD, OLED, USD, UFS, Sale, Smartphone, Mobile operating system, Hasselblad, Carbon, Immersion, UFS 4.0, Amazon, AMOLED, OIS, CAD, Microsoft OneNote, SONY, Heart, Autofocus, Light, Gmail, WhatsApp, OpenCanvas, HBM, Pixel, Open, LPDDR5X, Camera, Video game, Television, Online shopping

NEW YORK, Oct. 19, 2023 /PRNewswire/ -- Global technology brand OnePlus today announced the global launch of its new folding flagship smartphone, the OnePlus Open. As the first of its kind for OnePlus, the OnePlus Open is set to disrupt the foldable market with its uncompromising specifications. It brings together OnePlus' signature Fast & Smooth user experience, a premium camera experience in partnership with Hasselblad, and immersive spatial entertainment – all in an ultra-portable, modern and elegant foldable design.

Key Points: 
  • As the first of its kind for OnePlus, the OnePlus Open is set to disrupt the foldable market with its uncompromising specifications.
  • "With the launch of the OnePlus Open, we are thrilled to bring an uncompromising flagship foldable experience to users worldwide.
  • As OnePlus' first folding flagship, the OnePlus Open perfectly inherits the brand's iconic design philosophy — industrial minimalism combined with elegant sophistication.
  • The OnePlus Open is the first foldable smartphone to debut the Sony LYT-T808, its new line of revolutionary image sensors.

Flexion achieves Select Tier Status within the AWS Partner Network

Retrieved on: 
Monday, July 10, 2023
General Services Administration, DRC, VMware, Platform as a service, Infrastructure as a service, Amazon Web Services, Investment company, Certification, Medicare, Organization, Amazon, Anatomical terms of motion, Tax court, Korea Disease Control and Prevention Agency, Knowledge, AWS, United States Tax Court, APN, Internet service provider, Medicaid

MADISON, WI., July 10, 2023 (GLOBE NEWSWIRE) -- Flexion is pleased to announce that it has achieved the Amazon Web Services (AWS) Select Tier Partner status within the AWS Partner Network (APN).

Key Points: 
  • MADISON, WI., July 10, 2023 (GLOBE NEWSWIRE) -- Flexion is pleased to announce that it has achieved the Amazon Web Services (AWS) Select Tier Partner status within the AWS Partner Network (APN).
  • AWS Select Tier Services Partners are organizations recognized for proven technical expertise and demonstrated customer experience.
  • According to Scott Hasse, Flexion’s Chief Technical Officer, “Flexion has a long history of successfully developing solutions built on AWS.
  • We are excited by the opportunity to continue to develop our working relationship with AWS as an AWS Select Tier Partner, now and into the future.”
    Flexion has been delivering critical digital and cloud modernization initiatives on AWS for over ten years.

Nido Biosciences Emerges as Clinical Stage Company Raising $109 Million to Advance Treatments for Debilitating Neurological Diseases

Retrieved on: 
Monday, May 15, 2023
Professional Services, Health, Neurology, Genetics, Venture Capital, Clinical Trials, Biotechnology, Drug development, Cell death, Doctor of Philosophy, Initiative, Nido, DSM-IV codes, SBMA, Flagship Pioneering, Alexion Pharmaceuticals, Lilly, Patient, Anatomical terms of motion, Series, Spinal and bulbar muscular atrophy, Biology, Eli Lilly and Company, Protein, Therapy, ALS, FTD, Flexion Therapeutics, AR, Disease, Pharmaceutical industry, Management

Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, emerged from stealth today backed by an industry leading investor syndicate and having raised a combined $109 million in Seed, Series A and B financings.

Key Points: 
  • Nido Biosciences (Nido Bio), a clinical stage company developing precision medicines for debilitating neurological diseases, emerged from stealth today backed by an industry leading investor syndicate and having raised a combined $109 million in Seed, Series A and B financings.
  • Bioluminescence Ventures led the Series B round with participation from additional new investors and the noted insiders.
  • Nido Bio is leveraging advancements in the understanding of human genetics and disease to develop a sustainable pipeline of novel small molecule medicines to improve the daily lives of patients suffering from neurological diseases.
  • Across its programs, Nido Bio is addressing the fundamental biology of disease to restore healthy cell function.

Flexion and Digital Turbine Announce Strategic Partnership to Unlock Alternative App Distribution and Superior Monetization

Retrieved on: 
Monday, March 20, 2023
Partnership, Marketing, EVP, ONE, Huawei AppGallery, Android, Samsung Galaxy Store, Amazon Appstore, New Partnership for Africa's Development, Acquisition, Corporation, Carrier, OEM, Environment, Mobile phone, Video game, Aptoide, Anatomical terms of motion

AUSTIN, Texas and LONDON, March 20, 2023 /PRNewswire/ -- Flexion (NASDAQ Stockholm: FLEXM), the games marketing company and Digital Turbine (NASDAQ: APPS), the global leaders in growth solutions for the mobile ecosystem, today announced a strategic commercial relationship to grow game developers' audiences on some of the world's largest telecom platforms - boosting app discovery and revenue. 

Key Points: 
  • DT Hub , Digital Turbine's alternative mobile growth suite, enables its mobile operator partners to offer their customers a highly curated environment for premium app discovery.
  • DT Hub simplifies discovery and allows for simple and efficient direct-to-consumer app distribution.
  • "This partnership with Digital Turbine has all the ingredients to succeed in terms of creating new revenue, distribution, and marketing opportunities for game developers beyond traditional app stores.
  • The partnership with Flexion follows a strategic investment in Aptoide that Digital Turbine announced in October 2022 to build new innovative distribution products for Digital Turbine's mobile carriers, OEM, and app developer partners.

Neosoma Expands Its Board of Directors with Debbie Millin and Frederick Driscoll

Retrieved on: 
Wednesday, March 15, 2023
Neurology, Software, Oncology, Health, Artificial Intelligence, Medical Devices, Health Technology, Technology, Harvard Club of Boston, CCA Global Partners, Software as a service, Therapy, Sale, Trustee, Brain, Accounting, Flexion Therapeutics, Anatomical terms of motion, Chiba Museum of Science and Industry, Physician, Museum, Bentley University, Growth, Financial management, Culture, Harvard Business School, Neuro, Entrepreneurship, Management, Science

Neosoma, Inc. , an innovative medical technology company focused on helping clinicians advance the treatment of brain cancers, announces today it has appointed Debbie Millin and Frederick Driscoll to its board of directors.

Key Points: 
  • Neosoma, Inc. , an innovative medical technology company focused on helping clinicians advance the treatment of brain cancers, announces today it has appointed Debbie Millin and Frederick Driscoll to its board of directors.
  • “Key to executing on our strategy is ensuring that the company has a diverse and experienced board of directors,” said Ken Kolodziej, Neosoma’s CEO and Co-Founder.
  • Debbie also serves on multiple committees for the Board of Trustees at the Museum of Science in Boston, and the Harvard Club of Boston.
  • Frederick Driscoll is an accomplished healthcare executive with more than 25 years of financial management of life sciences companies.

Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results

Retrieved on: 
Tuesday, February 28, 2023
Telephone, Interest, Knee, Depreciation, SG, Conference call, Cadaver, Artificial intelligence, Research, GAAP, Annual general meeting, Brain, Acquisition, Webcast, Investment, Patient, R, Regulation of tobacco by the U.S. Food and Drug Administration, Amal Women's Training Center and Moroccan Restaurant, Growth, Spasticity, Tax, Bank statement, Table, Osteoarthritis, New Drug Application, Bupivacaine, Shanda, Conference, PIN, Sale, Cold therapy, Food, Hydrogen chloride, Bank, Video game, Life insurance, Reinsurance, Pharmaceutical industry, Security (finance), Cryptocurrency, EBITDA, Anatomical terms of motion

TAMPA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2022.

Key Points: 
  • ET —
    TAMPA, Fla., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported financial results for the fourth quarter and full-year of 2022.
  • Fourth quarter 2022 iovera° net product sales were $4.6 million, a 7% decrease versus the $4.9 million reported in the fourth quarter of 2021.
  • Total operating expenses were $181.8 million in the fourth quarter of 2022, versus the $155.0 million reported for the fourth quarter of 2021.
  • Cash provided by operations was $42.0 million in the fourth quarter of 2022, compared to $23.2 million in the fourth quarter of 2021.

Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million

Retrieved on: 
Thursday, January 5, 2023
Bupivacaine, EBITDA, Therapy, Flexion Therapeutics, COVID-19, Acquisition, Growth, 340B Drug Pricing Program, Pharmaceutical industry, Animal, Lithium, Anatomical terms of motion

TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 million for 2021, representing an increase of 23.1 percent.

Key Points: 
  • TAMPA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $666.8 million for 2022, compared with $541.5 million for 2021, representing an increase of 23.1 percent.
  • ZILRETTA net product sales of $28.0 million and $12.7 million for the fourth quarters of 2022 and 2021, respectively, and $9.4 million and $8.9 million for the months of December 2022 and 2021, respectively.
  • Other revenue, including sales of bupivacaine liposome injectable suspension, royalties and collaborative licensing revenue, was $1.4 million and $1.8 million in the fourth quarters of 2022 and 2021 and $1.4 million and $0.7 million for the months of December 2022 and 2021, respectively.
  • Other revenue, including sales of bupivacaine liposome injectable suspension, royalties and collaborative licensing revenue was $9.1 million in 2022, compared with $6.2 million in 2021.

Education for Peace & Security: UN Day Statement by Education Cannot Wait Director Yasmine Sherif

Retrieved on: 
Monday, October 24, 2022
Education, Anatomical terms of motion, Sahel, Conference, Hope, Private sector, Federal government of Switzerland, First Nations in Ontario, Multimedia, Safe Schools Declaration, United Nations Office at Geneva, Adolescence, Learning, International humanitarian law, United Nations Day, United Nations, Optimism, Charter of the United Nations, UN, Maintenance, Child, ECW, School, Birth control, Tourism, Emergency

In 1945 and the ensuing years, there was optimism, hope and determination to achieve peace, security and human rights for all.

Key Points: 
  • In 1945 and the ensuing years, there was optimism, hope and determination to achieve peace, security and human rights for all.
  • Since its formation in 1945, the United Nations has stood as a universal symbol of hope and humanity.
  • The UN Charter encompasses our vision for sustainable development, respect for human rights, and maintenance of peace and security.
  • Without education especially for those suffering in wars, climate disasters and as forcibly displaced how can we ever achieve the vision of the United Nations?

Education for Peace & Security: UN Day Statement by Education Cannot Wait Director Yasmine Sherif

Retrieved on: 
Monday, October 24, 2022
Education, Anatomical terms of motion, Sahel, Conference, Hope, Private sector, Federal government of Switzerland, First Nations in Ontario, Safe Schools Declaration, United Nations Office at Geneva, Adolescence, Learning, International humanitarian law, United Nations Day, United Nations, Optimism, Charter of the United Nations, UN, Maintenance, Child, ECW, School, Birth control, Tourism, Emergency

In 1945 and the ensuing years, there was optimism, hope and determination to achieve peace, security and human rights for all.

Key Points: 
  • In 1945 and the ensuing years, there was optimism, hope and determination to achieve peace, security and human rights for all.
  • Since its formation in 1945, the United Nations has stood as a universal symbol of hope and humanity.
  • The UN Charter encompasses our vision for sustainable development, respect for human rights, and maintenance of peace and security.
  • Without education especially for those suffering in wars, climate disasters and as forcibly displaced how can we ever achieve the vision of the United Nations?